Hydroxy and alkoxy substituted 1
1H-Imidazo[4,5-c]naphthyridin-4-amines with a hydroxy, alkoxy, hydroxyalkoxy, or alkoxyalkoxy substituent at the 2-position, pharmaceutical compositions containing these compounds, methods of making the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.
1. A compound of the Formula I:
wherein:
R 2 is selected from the group consisting of hydrogen, C 1-4 alkyl, hydroxyC 2-4 alkylenyl, and C 1-4 alkoxyC 2-4 alkylenyl;
R 1 is selected from the group consisting of benzyl, 1-phenylethyl, and pyridinylmethyl, each of which is unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, haloalkyl, haloalkoxy, and halogen; and tetrahydropyranylmethyl;
R A and R B taken together form a fused pyridine ring that is unsubstituted or substituted by one R 3 group, or substituted by one R 3 group and one R group, or substituted by one or more R groups;
or R A and R B taken together form a fused tetrahydropyridine ring that is unsubstituted or substituted by one or more R groups;
R is selected from the group consisting of:
halogen,
hydroxy,
alkyl,
alkenyl,
haloalkyl,
alkoxy,
alkylthio, and —N(R 9 ) 2 ;
R 3 is selected from the group consisting of:
—Z—R 4 ,
—Z—X—R 4 ,
—Z—X—Y—R 4 ,
—Z—X—Y—X—Y—R 4 , and
—Z—X—R 5 ;
X is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated by arylene, heteroarylene or heterocyclylene and optionally interrupted by one or more —O— groups;
Y is selected from the group consisting of:
—O—,
—S(O) 0-2 —,
—S(O) 2 —N(R 8 )—,
—C(R 6 )—,
—C(R 6 )—O—,
—O—C(R 6 )—,
—O—C(O)—O—,
—N(R 8 )-Q-,
—C(R 6 )—N(R 8 )—,
—O—C(R 6 )—N(R 8 )—,
—C(R 6 )—N(OR 9 )—,
—O—N(R 8 )-Q-,
—O—N═C(R 4 )—,
—C(═N—O—R 8 )—,
—CH(—N(—O—R 8 )-Q-R 4 )—,
Z is a bond or —O—;
R 4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl; alkoxy; hydroxyalkyl; haloalkyl; haloalkoxy; halogen; nitro; hydroxy; mercapto; cyano; aryl; aryloxy; arylalkyleneoxy; heteroaryl; heteroaryloxy; heteroarylalkyleneoxy; heterocyclyl; amino; alkylamino; dialkylamino; (dialkylamino)alkyleneoxy; and, in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;
R 5 is selected from the group consisting of:
R 6 is selected from the group consisting of ═O and ═S;
R 7 is C 2-7 alkylene;
R 8 is selected from the group consisting of hydrogen, C 1-10 alkyl, C 2-10 alkenyl, hydroxy-C 1-10 alkylenyl, C 1-10 alkoxy-C 1-10 alkylenyl, aryl-C 1-10 alkylenyl, and heteroaryl-C 1-10 alkylenyl;
R 9 is selected from the group consisting of hydrogen and alkyl;
R 10 is C 3-8 alkylene;
A is selected from the group consisting of —CH 2 —, —O—, —C(O)—, —S(O) 0-2 —, and —N(-Q-R 4 )—;
A′ is selected from the group consisting of —O—, —S(O) 0-2 —, —N(-Q-R 4 )—, and —CH 2 —;
Q is selected from the group consisting of a bond, —C(R 6 )—, —C(R 6 )—C(R 6 )—, —S(O) 2 —, —C(R 6 )—N(R 8 )—W—, —S(O) 2 —N(R 8 )—, —C(R 6 )—O—, —C(R 6 )—S—, and —C(R 6 )—N(OR 9 )—;
V is selected from the group consisting of —C(R 6 )—, —O—C(R 6 )—, —N(R 8 )—C(R 6 )—, and —S(O) 2 —;
W is selected from the group consisting of a bond, —C(O)—, and —S(O) 2 —; and
a and b are independently integers from 1 to 6 with the proviso that a+b is ≦7;
or a pharmaceutically acceptable salt thereof.
2. A compound selected from the group consisting of the Formulas II, III, IV, and V:
wherein:
R 2 is selected from the group consisting of hydrogen, C 1-4 alkyl, hydroxyC 2-4 alkylenyl, and C 1-4 alkoxyC 2-4 alkylenyl;
R is selected from the group consisting of:
halogen,
hydroxy,
alkyl,
alkenyl,
haloalkyl,
alkoxy,
alkylthio, and
—N(R 9 ) 2 ;
n is an integer from 0 to 3;
R 1 is selected from the group consisting of benzyl, 1-phenylethyl, and pyridinylmethyl, each of which is unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, haloalkyl, haloalkoxy, and halogen; and tetrahydropyranylmethyl;
R 3 is selected from the group consisting of:
—Z—R 4 ,
—Z—X—R 4 ,
—Z—X—Y—R 4 ,
—Z—X—Y—X—Y—R 4 , and
—Z—X—R 5 ;
m is 0 or 1; with the proviso that when m is 1, then n is 0 or 1;
X is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated by arylene, heteroarylene or heterocyclylene and optionally interrupted by one or more —O— groups;
Y is selected from the group consisting of:
—O—,
—S(O) 0-2 —,
—S(O) 2 —N(R 8 )—,
—C(R 6 )—,
—C(R 6 )—O—,
—O—C(R 6 )—,
—O—C(O)—O—,
—N(R 8 )-Q-,
—C(R 6 )—N(R 8 )—,
—O—C(R 6 )—N(R 8 )—,
—C(R 6 )—N(OR 9 )—,
—O—N(R 8 )-Q-,
—O—N═C(R 4 )—,
—C(═N—O—R 8 )—,
—CH(—N(—O—R 8 )-Q-R 4 )—,
Z is a bond or —O—;
R 4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl; alkoxy; hydroxyalkyl; haloalkyl; haloalkoxy; halogen; nitro; hydroxy; mercapto; cyano; aryl; aryloxy; arylalkyleneoxy; heteroaryl; heteroaryloxy; heteroarylalkyleneoxy; heterocyclyl; amino; alkylamino; dialkylamino; (dialkylamino)alkyleneoxy; and, in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;
R 5 is selected from the group consisting of:
R 6 is selected from the group consisting of ═O and ═S;
R 7 is C 2-7 alkylene;
R 8 is selected from the group consisting of hydrogen, C 1-10 alkyl, C 2-10 alkenyl, hydroxy-C 1-10 alkylenyl, C 1-10 alkoxy-C 1-10 alkylenyl, aryl-C 1-10 alkylenyl, and heteroaryl-C 1-10 alkylenyl;
R 9 is selected from the group consisting of hydrogen and alkyl;
R 10 is C 3-8 alkylene;
A is selected from the group consisting of —CH 2 —, —O—, —C(O)—, —S(O) 0-2 —, and —N(-Q-R 4 )—;
A′ is selected from the group consisting of —O—, —S(O) 0-2 —, —N(-Q-R 4 )—, and —CH 2 —;
Q is selected from the group consisting of a bond, —C(R 6 )—, —C(R 6 )—C(R 6 )—, —S(O) 2 —, —C(R 6 )—N(R 8 )—W—, —S(O) 2 —N(R 8 )—, —C(R 6 )—O—, —C(R 6 )—S—, and —C(R 6 )—N(OR 9 )—;
V is selected from the group consisting of —C(R 6 )—, —O—C(R 6 )—, —N(R 8 )—C(R 6 )—, and —S(O) 2 —;
W is selected from the group consisting of a bond, —C(O)—, and —S(O) 2 —; and
a and b are independently integers from 1 to 6 with the proviso that a+b is ≦7;
or a pharmaceutically acceptable salt thereof.
3. The compound or salt of claim 2 wherein the compound is of the Formula II:
or a pharmaceutically acceptable salt thereof.
4. A compound selected from the group consisting of the Formulas VI, VII, VIII, and IX:
wherein:
R 2 is selected from the group consisting of hydrogen, C 1-4 alkyl, hydroxyC 2-4 alkylenyl, and C 1-4 alkoxyC 2-4 alkylenyl;
R is selected from the group consisting of:
halogen,
hydroxy,
alkyl,
alkenyl,
haloalkyl,
alkoxy,
alkylthio, and
—N(R 9 ) 2 ;
n is an integer from 0 to 3; and
R 1 is selected from the group consisting of benzyl, 1-phenylethyl, and pyridinylmethyl, each of which is unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, haloalkyl, haloalkoxy, and halogen; and tetrahydropyranylmethyl;
or a pharmaceutically acceptable salt thereof.
5. The compound or salt of claim 4 wherein the compound is of the Formula VI:
or a pharmaceutically acceptable salt thereof.
6. The compound or salt of claim 2 wherein m is 0.
7. The compound or salt of claim 2 wherein R 3 is at the 7-position.
8. The compound or salt of claim 1 wherein R 3 is pyridin-3-yl, 3-hydroxyphenyl, 4-hydroxymethylphenyl, or benzyloxy.
9. The compound or salt of claim 1 wherein R is hydroxy.
10. The compound or salt of claim 1 wherein R 2 is hydrogen.
11. The compound or salt of claim 1 wherein R 1 is selected from the group consisting of benzyl, 4-methoxybenzyl, 1-phenylethyl, and pyridin-3-ylmethyl.
12. The compound or salt of claim 11 wherein R 1 is selected from the group consisting of benzyl and 1-phenylethyl.
13. The compound or salt of claim 1 wherein R 1 is tetrahydro-2H-pyran-4-ylmethyl.
14. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 1 and a pharmaceutically acceptable carrier.